iCAD, a medical technology company, has been granted a license to use the research model from Google. The hope is that the technology will lead to more accurate breast cancer detection.
The two companies hope to eventually deploy the technology in real-world clinical settings. Commercial deployment is dependent on how successful research and testing are. We will move deliberately and test things as we go.
We will move as we go.
The partnership builds on the work done by the search engine. In 2020 a paper was published in the journal Nature that showed that its artificial intelligence system was better at identifying signs of breast cancer. The model was able to reduce false negatives by up to 9.4 percent and false positives by up to 5.7 percent.
iCAD plans to use a research model from the internet giant. There is a tool called ProFound that analyzes images from digital breast tomosynthesis. The tool looks for soft tissue density and calcifications.
The hope is that artificial intelligence can be used to help patients. Medical experts are cautious when it comes to using artificial intelligence. Some instances in the research were when the model didn't initially see cancer. There isn't a gold standard for detecting cancer beyond that. It might be hard to establish a good baseline when training an algorithm. More than two options to account for the "gray area of diagnosis" might improve the use of artificial intelligence tools. When it comes to trying to detect early-stage cancer, relying too heavily on artificial intelligence without bringing in doctors could increase the risk of overdiagnosis.
The UK's National Health Service and Imperial College London are working with Google to see if its artificial intelligence can be used as a second independent reader in mammograms.
All Rights Reserved © 2024
